Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
GlucoTrack ( (GCTK) ) has issued an announcement.
On December 29, 2025, Glucotrack, Inc. entered into a securities purchase agreement with a single institutional investor for a private placement of pre-funded warrants and common warrants (or common stock equivalents) priced at-the-market under Nasdaq rules, raising approximately $4.0 million in gross proceeds at an effective combined price of $3.87 per share and warrant, with closing occurring on December 31, 2025. The financing, conducted through Curvature Securities LLC as sole placement agent, includes lock-up commitments from officers and directors, ownership caps on warrant exercises, restrictions on additional equity issuance and variable-rate financings for defined periods, and a registration rights framework that will require Glucotrack to register the resale of the underlying securities, collectively reinforcing its near-term capital position for working capital and general corporate purposes while constraining dilution pathways and shaping its funding strategy over the next year.
The most recent analyst rating on (GCTK) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on GlucoTrack stock, see the GCTK Stock Forecast page.
Spark’s Take on GCTK Stock
According to Spark, TipRanks’ AI Analyst, GCTK is a Neutral.
The score is driven down primarily by very poor financial performance (minimal revenue, widening losses, heavy cash burn, and negative equity). Technical indicators also remain broadly bearish with price below key moving averages, despite oversold readings. Valuation offers limited support because the company is loss-making and does not pay a dividend.
To see Spark’s full report on GCTK stock, click here.
More about GlucoTrack
Glucotrack, Inc. (Nasdaq: GCTK) is a medical technology company focused on designing, developing and commercializing novel technologies for people with diabetes, currently centered on a long-term implantable continuous blood glucose monitoring (CBGM) system with a projected three-year sensor life, no on-body wearable component and minimal calibration, which remains an investigational device under U.S. law.
Average Trading Volume: 62,098
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.52M
See more data about GCTK stock on TipRanks’ Stock Analysis page.